Skip to content

Tinnitus Treatment Report

News
Research
Clinical Trials
Projects
Discussion

Progenitor Cell Activation

News

Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration

Enter your email address

Phone

This field is for validation purposes and should be left unchanged.

Donate
Contact
Subscribe

Address

Urgent Research LLC
7207 N Shadeland Ave Suite C
Indianapolis, IN 46250

The content on this website is not a substitute for professional medical advice, diagnosis, or treatment. Never ignore professional medical advice or delay in seeking it because of something you have read on this website. Always talk to your doctor or other qualified healthcare provider with any questions you may have regarding a medical condition. Any mention of products, services or companies is not meant as a guarantee, endorsement, or recommendation. This website is independent and unaffiliated. No conflicts of interest to disclose.

Copyright © 2024 Urgent Research LLC